Intellia Therapeutics presents Phase 1/2 data on lonvo-z

Intellia Therapeutics (NTLA) presented positive clinical data from a pooled analysis of all patients who received a 50 milligram dose of lonvo-z in the company’s ongoing Phase 1/2 clinical trial in patients with hereditary angioedema. These results were shared in an oral presentation today at the American College of Allergy, Asthma & Immunology, ACAAI, 2025 Annual Scientific Meeting in Orlando, Florida. Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 were attack-free and long-term prophylaxis -free; 24 were attack-free and LTP-free for at least seven months; Among the 11 patients who originally received a 50 mg dose in Phase 2, 10 were attack-free and LTP-free. Continue to observe a well-tolerated safety profile with up to three years of patient follow-up and no new long-term risks identified